患者由来異種移植モデルの世界市場規模：がんタイプ別、組織源別、用途別、地域別、範囲および予測

患者由来異種移植（PDX）モデルの市場規模および予測

患者由来異種移植（PDX）モデルの市場規模は、2024年に2億5,896万米ドルと評価され、2024年から2031年にかけて16.60%のCAGRで成長し、2031年には7億9,482万米ドルに達すると予測されています。患者由来異種移植（PDX）モデルは、がん研究や治療開発において洗練された非常に有用なツールです。このモデルには、ヒト腫瘍組織を免疫不全マウスに直接移植する方法が含まれます。標準的な細胞株モデルと比較して、PDXモデルはオリジナルのヒト腫瘍の組織学的構造や遺伝的特性を保持しているため、患者における腫瘍の活動性を非常にリアルに再現することができます。

PDXモデルは、従来の細胞株モデルよりも実際の悪性腫瘍をより正確に描写できるため、がん研究においてますます重要になってきています。PDXモデルの最も一般的な用途の一つは、前臨床薬の開発と試験です。研究者は、ヒト腫瘍組織を免疫不全マウスに直接移植することにより、患者の腫瘍の組織学的特徴、遺伝的多様性、不均一性を保持することができます。

がん研究や個別化治療における患者由来異種移植（PDX）モデルの将来的な利用は、多くの悪性腫瘍の理解と治療を一変させる可能性を秘めています。ヒト腫瘍組織を免疫不全マウスに移植するPDXモデルは、ヒト腫瘍の複雑さと異質性を正確に模倣することができるため、その価値はますます高まっています。

患者由来異種移植（PDX）モデルの世界市場力学

世界の患者由来異種移植（PDX）モデル市場を形成している主な市場力学

主な市場促進要因

個別化治療に対する需要の高まり

PDXモデルの最も重要な市場促進要因の1つは、個別化治療へのシフトです。個別化医療は、遺伝学、ライフスタイル、環境に基づいて、個々の患者に治療ソリューションを個別化しようとするものです。ヒト腫瘍組織を免疫不全マウスに移植するPDXモデルは、遺伝的多様性、不均一性、微小環境といったヒトがんの生物学的特性を忠実に模倣しています。

がん研究の進歩：

がん研究の著しい進歩もPDXモデル産業の拡大を後押ししています。細胞株や遺伝子改変マウスのような従来のがんモデルでは、ヒトの複雑な悪性腫瘍を再現できないことが多く、その結果、医薬品開発において高い減少率を示しています。しかし、PDXモデルはヒトのがん生物学のより正確な像を提供し、前臨床研究においてより高い予後結果をもたらします。

がん罹患率の増加

がん罹患率の世界の増加は、PDXモデル産業のもう一つの主要な促進要因です。世界保健機関（WHO）によると、がんは世界の死亡原因の一つであり、2020年には約1,000万人が死亡するとされています。がん罹患率の増加は、より効果的でカスタマイズされた治療オプションの必要性を促し、PDXモデルの需要を高めています。

主な課題

ばらつきと再現性

PDXモデルの主な懸念事項の一つは、その固有のばらつきと再現性の欠如です。腫瘍の起源、移植の方法、患者の腫瘍の生物学的特性など、数多くの要因がPDXモデルの有効性に影響を与えうる。これらのパラメータにばらつきがあると、腫瘍の発生パターンや治療効果に大きな変化が生じる可能性があります。

免疫系の違い

PDXモデルに免疫不全マウスを用いると、宿主の免疫系が排除されるため、免疫細胞と相互作用するヒトのがんを研究する際に大きな不利となります。これらの動物には免疫系がないため、腫瘍の増殖や薬物反応に重要な免疫学的環境を表現することができないです。

倫理的およびロジスティック上の問題：PDXモデルの作製と維持には、いくつかの倫理的および実際的な問題があります。PDXモデルの作成には、患者から腫瘍サンプルを採取する必要があるが、これには侵襲的な処置が含まれ、患者にとって負担となり、同意やヒト組織の取り扱いに関する倫理的な懸念が生じる。

主要動向：

個別化医療のためのカスタマイズの強化

PDXモデルの最も注目すべき動向の一つは、個別化医療における利用の拡大です。研究者はPDXモデルを用いて、治療に対する個人の反応をよりよく予測できる患者特異的腫瘍モデルを作製しています。このカスタマイズには、患者の腫瘍組織を免疫不全マウスに移植することが必要であり、このマウスはオリジナルの腫瘍の不均一性を発達させ、模倣します。

ゲノムおよびオミックスデータとの統合：

PDXモデルとゲノムおよびオミックスデータの統合は、もう一つの重要な動向です。ハイスループットシーケンスや分子プロファイリングの進歩により、研究者は腫瘍の遺伝学的特徴や分子的特徴をより深く理解することができるようになった。PDXモデルは、これらの結果を検証し、遺伝子変異や分子経路が薬物反応性にどのように影響するかを調べるために、ますます利用されるようになっています。

新規がん種と薬物併用療法への拡大

PDXモデルの使用を新規のがん種や薬剤の組み合わせにまで拡大する傾向が顕著です。以前は乳がんや肺がんのようなよく特徴付けられた疾患に利用されていたPDXモデルが、現在では膵臓がんや脳腫瘍を含むより稀で困難ながんの治療に利用されています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 患者由来異種移植（PDX）モデル市場：がんタイプ別

• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん

第5章 患者由来異種移植（PDX）モデル市場：組織源別

• 固形腫瘍
• 血液悪性腫瘍

第6章 患者由来異種移植（PDX）モデル市場：用途別

• 前臨床医薬品開発
• バイオマーカー解析
• 精密医療
• 毒性試験

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Crown Bioscience Inc
• WuXi AppTec
• Champions Oncology
• The Jackson Laboratory
• Charles River Laboratories International Inc
• Taconic Biosciences Inc
• Oncodesign Precision Medicine
• Inotiv Inc
• EPO Berlin-Buch GmbH
• Xentech

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Patient Derived Xenograft (PDX) Models Market Size and Forecast

Patient Derived Xenograft (PDX) Models Market size was valued at USD 258.96 Million in 2024 and is projected to reach USD 794.82 Million by 2031, growing at a CAGR of 16.60% from 2024 to 2031. Patient-Derived Xenograft (PDX) models are a sophisticated and extremely useful tool in cancer research and therapeutic development. These models include transplanting human tumor tissue directly into immunocompromised mice. Compared to standard cell line models, PDX models preserve the histological architecture and genetic properties of the original human tumor making them highly realistic of the tumor's activity in the patient.

They are becoming increasingly important in cancer research as they provide a more accurate portrayal of actual malignancies than traditional cell line models. One of the most common applications for PDX models is preclinical drug development and testing. Researchers can preserve the patient's tumor's histological traits, genetic variety, and heterogeneity by directly implanting human tumor tissues into immunodeficient mice.

The future use of patient-derived xenograft (PDX) models in cancer research and personalized therapy has the potential to transform our understanding and treatment of many malignancies. PDX models which entail implanting human tumor tissues into immunodeficient mice are becoming increasingly valuable due to their ability to accurately imitate the complexity and heterogeneity of human tumors.

Global Patient Derived Xenograft (PDX) Models Market Dynamics

The key market dynamics that are shaping the global patient derived xenograft (PDX) Models market include:

Key Market Drivers:

Rising Demand for Personalized Treatment:

One of the most important market drivers for PDX models is the shift to personalized treatment. Personalized medicine seeks to personalize treatment solutions to individual patients based on their genetics, lifestyle, and environment. PDX models which entail implanting human tumor tissues into immunodeficient mice, closely mimic the biological properties of human cancers, such as genetic variety, heterogeneity, and the microenvironment.

Advancements in Cancer Research:

Significant advances in cancer research are also driving the expansion of the PDX models industry. Traditional cancer models such as cell lines and genetically engineered mice models, frequently fail to replicate the complexities of human malignancies resulting in high attrition rates in drug development. However, PDX models provide a more accurate picture of human cancer biology resulting in higher prognostic outcomes in preclinical studies.

Increasing Cancer Prevalence

: The global growth in cancer incidence is another major driver of the PDX models industry. According to the World Health Organization (WHO), cancer is one of the main causes of mortality globally accounting for nearly 10 million deaths in 2020. The rising incidence of cancer is driving the need for more effective and customized treatment options which is growing demand for PDX models.

Key Challenges:

Variability and Reproducibility

: One of the key concerns with PDX models is their inherent variability and lack of reproducibility. Numerous factors can influence the effectiveness of a PDX model including the origin of the tumor, the manner of implantation, and the biological properties of the patient's tumor. Variations in these parameters can cause major changes in tumor development patterns and treatment responses.

Immune System Differences

: Using immunodeficient mice in PDX models eliminates the host immune system which is a major disadvantage when investigating human cancers that interact with immune cells. Because these animals lack an immune system, they do not represent the immunological milieu which is critical for tumor growth and medication response.

Ethical and Logistical Concerns: The creation and maintenance of PDX models raises several ethical and practical issues. Creating PDX models necessitates the collecting of tumor samples from patients which includes invasive procedures that can be burdensome for patients and raise ethical concerns about consent and the handling of human tissues.

Key Trends:

Enhanced Customization for Personalized Medicine:

One of the most notable trends in PDX models is their growing usage in personalized medicine. Researchers are using PDX models to create patient-specific tumor models that can better predict individual responses to treatment. This customization entails implanting patient tumor tissues into immunodeficient mice which develop and mimic the original tumor's heterogeneity.

Integration with Genomic and Omics Data:

Integrating PDX models with genomic and omics data is another critical trend. Advances in high-throughput sequencing and molecular profiling have allowed researchers to get a better understanding of tumor genetics and molecular features. PDX models are increasingly being utilized to validate these results and investigate how genetic variants and molecular pathways influence medication responsiveness.

Expansion into Novel Cancer Types and Medication Combinations

: There is a noticeable trend of extending the use of PDX models to novel cancer types and medication combinations. PDX models which were previously utilized for well-characterized diseases like breast and lung cancer are now being used to treat rarer and more difficult cancers including pancreatic and brain tumors.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Patient Derived Xenograft (PDX) Models Market Regional Analysis

Here is a more detailed regional analysis of the global patient derived xenograft (PDX) Models market:

North America:

In North America, the patient-derived xenograft (PDX) models market is dominant driven by increased oncology research and development activities as well as a growing emphasis on customized therapy. The region's global market leadership is supported by its advanced healthcare infrastructure, significant investment in research, and high cancer prevalence all of which drive demand for PDX models. The increasing expenditure on oncology research and development in North America is a major driver of the PDX model industry. According to the National Cancer Institute (NCI), the United States will invest nearly USD 7.5 Billion in cancer research in 2023 representing a significant increase over previous years.

Another significant factor is the growing emphasis on individualized medicine which is strongly aligned with the capabilities of PDX models. Personalized medicine seeks to personalize therapies to individual patients based on genetic, environmental, and lifestyle characteristics. PDX models are useful in this field because they allow researchers to investigate patient-specific cancers and test targeted medicines. The United States Food and Drug Administration (FDA) recognizes the importance of customized medicine, and in 2023, it approved a record number of personalized medicines reflecting the increased demand for models that can simulate unique patient reactions.

Asia Pacific:

The Patient Derived Xenograft (PDX) models market in Asia Pacific is expanding rapidly owing mostly to rising cancer incidence and the need for personalized therapy. China and Japan are the region's fastest-growing markets, due to massive investments in healthcare infrastructure and research. The increased incidence of cancer is a primary driver of the PDX models market in Asia Pacific. According to the World Health Organization (WHO), cancer is still the biggest cause of death in the region. In 2020, there are an anticipated 9.5 million new cancer cases and 5.4 million cancer deaths in Asia.

Another key factor is the increased emphasis on customized medicine which is rapidly gaining popularity in Asia Pacific. Personalized medicine seeks to customize treatments to individual genetic profiles, and PDX models play an important part in this effort by offering more realistic preclinical testing environments. The Japanese Ministry of Health, Labour, and Welfare announced that the government is heavily investing in customized medicine and genomics research with significant funds given to precision oncology efforts. This emphasis on individualized treatments drives up the need for PDX models which are critical for testing and validating innovative therapeutic approaches suited to individual patient's needs.

Global Patient Derived Xenograft (PDX) Models Market: Segmentation Analysis

The Global Patient Derived Xenograft (PDX) Models Market is segmented based on Type of Cancer, Source of Tissue, Application, and Geography.

Patient Derived Xenograft (PDX) Models Market, By Type of Cancer

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

Based on the Type of Cancer, the Global Patient Derived Xenograft (PDX) Models Market is bifurcated into Breast Cancer, Lung Cancer, Colorectal Cancer, and Prostate Cancer. In the global patient derived xenograft (PDX) Models Market, breast cancer models are the dominant segment. This dominance is primarily due to the high incidence of breast cancer globally and its complex biology which necessitates extensive research for effective treatments. PDX models for breast cancer are crucial for understanding tumor heterogeneity, drug resistance, and developing personalized therapies.

Patient Derived Xenograft (PDX) Models Market, By Source of Tissue

• Solid Tumors
• Hematological Malignancies

Based on the Source of Tissue, the Global Patient Derived Xenograft (PDX) Models Market is bifurcated into Solid Tumors, and Hematological Malignancies. In the patient derived xenograft (PDX) models market, solid tumors are the dominant segment. This dominance is due to the high prevalence of solid tumors compared to hematological malignancies and the extensive research and development focus on these models. The demand for PDX models of solid tumors is driven by their relevance in drug discovery, personalized medicine, and cancer research.

Patient Derived Xenograft (PDX) Models Market, By Application

• Preclinical Drug Development
• Biomarker Analysis
• Precision Medicine

Based on the Application, the Global Patient Derived Xenograft (PDX) Models Market is bifurcated into Preclinical Drug Development, Biomarker Analysis, and Precision Medicine. In the global patient derived xenograft (PDX) models market, preclinical drug development is the dominant application. This dominance stems from the critical role PDX models play in evaluating the efficacy and safety of new drug candidates before clinical trials. PDX models which involve implanting human tumors into immunocompromised mice, provide a more accurate representation of human cancer compared to traditional cell lines.

Patient Derived Xenograft (PDX) Models Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Patient Derived Xenograft (PDX) Models Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the patient derived xenograft (PDX) models market, North America holds the dominant position. This leadership is primarily due to advanced healthcare infrastructure, significant investment in research and development, and a high prevalence of cancer which drives demand for innovative cancer research models. The region's strong presence of leading pharmaceutical and biotechnology companies further supports this dominance by facilitating extensive research and clinical trials.

Key Players

• The "Global Patient Derived Xenograft (PDX) Models Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Crown Bioscience, Inc., WuXi AppTec, Champions Oncology, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., EPO Berlin-Buch GmbH, Xentech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Patient Derived Xenograft (PDX) Models Market Key Developments

• In July 2022, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has signed a strategic license deal with Charles River Laboratories, Inc. for the exclusive sale of their next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines in North America. Charles River will create foundation colonies, with commercially available versions starting in 2023.
• In April 2022, Professor Kamimura's research group at Niigata University developed a novel pancreatic cancer model in wild-type rats using the pancreas-targeted selective hydrodynamic gene delivery approach.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Patient Derived Xenograft (PDX) Models Market, By Type of Cancer

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

5. Patient Derived Xenograft (PDX) Models Market, By Source of Tissue

• Solid Tumors
• Hematological Malignancies

6. Patient Derived Xenograft (PDX) Models Market, By Application

• Preclinical Drug Development
• Biomarker Analysis
• Precision Medicine
• Toxicology Testing

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Crown Bioscience Inc
• WuXi AppTec
• Champions Oncology
• The Jackson Laboratory
• Charles River Laboratories International Inc
• Taconic Biosciences Inc
• Oncodesign Precision Medicine
• Inotiv Inc
• EPO Berlin-Buch GmbH
• Xentech

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References